Results 91 to 100 of about 46,898 (102)

CLL2-BIG - a Novel Treatment Regimen of Bendamustine Followed By GA101 and Ibrutinib Followed By Ibrutinib and GA101 Maintenance in Patients with Chronic Lymphocytic Leukemia (CLL): Interim Results of a Phase II-Trial

Blood, 2015
Julia Von Tresckow, Paula Cramer, Jasmin Bahlo   +2 more
exaly  

Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies

Blood, 2011
Manfred Schwaiger, Jerry W Slootstra, Karl-Peter Hopfner   +2 more
exaly  

CLL2-BIG - a Novel Treatment Regimen of Bendamustine Followed By GA101 and Ibrutinib Followed By Ibrutinib and GA101 Maintenance in Patients with Chronic Lymphocytic Leukemia (CLL): Results of a Phase II-Trial

Blood, 2016
Julia Von Tresckow, Jasmin Bahlo, Anja Engelke   +2 more
exaly  

Phase I Study of RO5072759 (GA101) in Relapsed/Refractory Chronic Lymphocytic Leukemia.

Blood, 2009
Guillaume Cartron, Catherine Thieblemont, Gilles Salles   +2 more
exaly  

Compared Antitumor Activity of GA101 and Rituximab against the Human RL Follicular Lymphoma Xenografts in SCID Beige Mice.

Blood, 2008
Lina Reslan, Charles Dumontet
exaly  

GA101, a Novel Humanized Type II CD20 Antibody with Glycoengineered Fc and Enhanced Cell Death Induction, Exhibits Superior Anti-Tumor Efficacy and Superior Tissue B Cell Depletion In Vivo.

Blood, 2007
Sondermann Peter, Christian Gerdes, Samuel Moser   +2 more
exaly  

GA101 (a Novel Anti-CD20 Monoclonal Antibody)-Induced Lichenoid Eruption

Dermatology and Therapy, 2012
exaly  

Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients

Blood, 2012
Gilles Salles, Catherine Thieblemont, Elina Asikanius   +2 more
exaly  

Encouraging Activity of Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma: Results From a Phase II Study (BO20999),

Blood, 2011
Philippe Solal-Celigny, Elisabeth Wassner-Fritsch, Elina Asikanius   +2 more
exaly  

Enhanced Activity of GA101, a Novel Type II, Glycoengineered CD20 Antibody, In Combination with Bendamustine or Fludarabine, and with the Bcl-2 Family Inhibitors ABT-737 or ABT-263

Blood, 2010
Frank Herting, Sabine Bader, Pablo Umana   +2 more
exaly